BOVICEF DC 250 MG INTRAMAMMARY SUSPENSION FOR CATTLE

Država: Irska

Jezik: engleski

Izvor: HPRA (Health Products Regulatory Authority)

Aktivni sastojci:

CEFALONIUM

Dostupno od:

Zoetis Ireland Limited

ATC koda:

QJ51D

INN (International ime):

CEFALONIUM

Doziranje:

250 Milligram

Farmaceutski oblik:

intramammary Suspension

Tip recepta:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapijska grupa:

Bovine

Područje terapije:

OTHER BETA-LACTAM ANTIBACTERIALS FOR INTRAMAMMARY USE

Terapijske indikacije:

Antibacterial

Status autorizacije:

Authorised

Datum autorizacije:

2015-08-07

Svojstava lijeka

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
BOVICEF DC 250 mg Intramammary Suspension for Cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 3 g intramammary syringe contains:
ACTIVE SUBSTANCE:
Cefalonium 250 mg (as cefalonium dihydrate).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Intramammary Suspension
Off-white to brownish suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (dry cow)
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of subclinical mastitis at drying-off and the
prevention of new bacterial infections of the udder during
the non-lactating period of cows caused by_ Staphylococcus aureus,
Streptococcus agalactiae, Streptococcus_
_dysgalactiae, Streptococcus uberis, Trueperella pyogenes, Escherichia
coli_ and_ Klebsiella_ spp_._
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to cephalosporins,
other
-lactam antibiotics or to any of the
excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_6_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_9_
_5_
_2_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Use of the product should be based on susceptibility testing of the
bacteria isolated from the animal. If this is not
possible, therapy should be based on local (regional, farm level)
epidemiologic